Stability of Melphalan Solution for Intravitreal Injection for Retinoblastoma

BUITRAGO E; LAGOMARSINO E; MATO G; SCHAIQUEVICH P

ARCHIVES OF OPHTHALMOLOGY

AMER MEDICAL ASSOC

Año: 2014

0003-9950

Intravitreal injections for the treatment of retinoblastoma have been 4 gaining relevance among ophthalmologists, supported by reports on outcome 5 and improvement of the administration technique. Currently, doses up to 30 μg per injection are used according to an extensively described technique for intravitreal injection that minimizesing the risk of extraocular dissemination of tumor cells. The commercial form of melphalan (Alkeran) contains 50 mg of 10 melphalan to be reconstituted in 10 mL of vehicle,3 but each intravitreal 11 injection consists of 30 μg of melphalan (its 1667th part). The rest of the vial is discarded. Specifically, in countries with limited resources, this procedure may be optimized to preventing disposal of active agent and preserveing it for future patients. In tThe package insert it is statedstates that after dilution 15 (